Sweeping New FTC Rules Could Chill Healthcare Mergers and Acquisitions
Proposed rule would require businesses to undergo even more stringent review to secure regulatory approval for such deals.
Already a member? Log in here
M&A and Strategic Deals: Thermo Fisher, BD, and Quest Use M&A to Advance Post-COVID-19 Strategies
Diagnostics companies that invested heavily in COVID-19 products are relying on M&A transactions to restructure and transition.
Already a member? Log in here
M&A & Strategic Dealmaking: Illumina May Finally Be Ready to Unwind GRAIL Acquisition
After an eventful month in the Illumina-GRAIL saga, the story may soon be over.
Already a member? Log in here
M&A & Strategic Deals: Dealmaking Shows New Signs of Life but FTC Scrutiny Casts a Dark Shadow
After a significant lull, M&As in the lab diagnostics space heated up in May, with several key deals announced.
Already a member? Log in here
Hostile Regulatory Environment Further Chills Diagnostics Market
The biggest story in M&A dealmaking continues to be the deal that’s being undone—Illumina’s acquisition of GRAIL.
Already a member? Log in here